Physician profile
Libby Going
NPI 1689916900
$747.58
in general payments reported to CMS, 2019-2025
19 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.73 · 2021: $68.53 · 2022: $302 · 2023: $23.94 · 2024: $154 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $328.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $108.79 | 2022 | |
| Astellas Pharma US INC | $91.99 | 2022 | |
| Janssen Biotech, INC. | $68.04 | 2025 | Tremfya, Simponi Aria |
| Global Blood Therapeutics, INC. | $58.77 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $47.97 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $46.83 | 2019-2022 | |
| Exact Sciences Corporation | $41.71 | 2023-2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $38.30 | 2024 | Yupelri |
| Phadia US INC. | $37.28 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $24.28 | 2022 | |
| Sun Pharmaceutical Industries INC. | $23.46 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $23.26 | 2024 | Crysvita |
| Amgen INC. | $23.25 | 2025 | Tezspire |
| Glaxosmithkline, LLC. | $22.75 | 2019 | |
| Pfizer INC. | $20.47 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $20.34 | 2025 | Heplisav-B |
| Organon LLC | $18.22 | 2025 | Nexplanon |
| Abbott Laboratories | $16.73 | 2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $15.14 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Libby Going listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.